Neuroendocrine Tumor

Diffuse nuclear "TPIT" staining with OTI2G1 in chordoma reflects cross-reactivity driven by conserved T-box structure rather than true TBX19 expression. For the differential diagnosis of sellar lesions, especially poorly differentiated chordoma versus pituitary neuroendocrine tumor, use of more specific clones (eg, CL6251) is recommended.

Liver lesions shrank after treatment with octreotide and Lutetium-177 vipivotide tetraxetan...The role of microsatellite instability (MSI) as a screening marker, and personalized treatment approaches like immunotherapy for dMMR tumors. Understanding these correlations may assist in early discovery, surveillance, and customized treatment for patients dealing with LS-associated malignancies.

Pituitary metastasis frequently presents with combined endocrine dysfunction and neuro-ophthalmologic compromise, occasionally as an acute sellar emergency. In oncologic patients with sellar lesions, the combination of AVP-D, visual deterioration, and non-prolactinoma-range hyperprolactinemia should raise suspicion for pituitary metastasis and prompt urgent endocrine and local evaluation.

The aim of this work is to evaluate [89Zr]Zr-DFO-TATE and [89Zr]Zr-DFO-TOC for PET imaging of SSTR+ NETs. This study seeks to provide a comprehensive in vivo comparison of the two agents including the in vivo PET imaging, ex vivo biodistribution, and internal radiation dosimetry, with the overarching goal of advancing precision diagnostics and improving therapeutic planning for NET patients undergoing [177Lu]Lu-DOTA-TATE therapy.

In addition, CLDN1-high tumors exhibited activation of epithelial-mesenchymal transition, HIPPO signaling, and immune-related pathways, together with increased stromal and immune cell infiltration. Collectively, our findings identify CLDN1 as a marker of a biologically distinct and clinically aggressive pNET subset characterized by dedifferentiation, lineage plasticity, and tumor microenvironment remodeling, supporting further evaluation of CLDN1 as a candidate prognostic biomarker and potential therapeutic target in pNETs.

The advent of these innovations generates questions, such as which tracers can be used in clinical practice, how to compare scans performed with different tracers, or can antagonists be used to select patients for peptide receptor radionuclide therapy? This 'controversy paper' from the European Neuroendocrine Tumor Society provides an overview of the relevant evidence to answer these questions, and provides guidance to clinicians and nuclear medicine physicians for contemporary use of SSTR PET.

The addition of everolimus, a mammalian target of rapamycin inhibitor, to octreotide marginally improves the 6-month progression-free survival (PFS) rate...We present the first case of a refractory meningioma patient treated with combination PRRT and octreotide in a 66-year-old male who received 177Lu-DOTATATE 7.4 GBq (200 mCi) and intramuscular long-acting octreotide 40 mg every 8 weeks for four cycles followed by a single cycle of octreotide 40 mg monotherapy...A 7-week post-treatment MRI brain demonstrated stable disease with 11.5% reduction per RANO-Meningioma and a 2.6% reduction per RECIST 1.1 criteria. Combined PRRT and octreotide represents a promising therapeutic strategy for patients with refractory meningioma.

With this aim we investigated INSM1 expression in 58 ACCs that, based on the expression of synaptophysin and chromogranin A, were separated into 36 pure ACCs lacking any neuroendocrine marker expression, 21 ACCs with divergent acinar and neuroendocrine differentiation, and one mixed neuroendocrine/non-neuroendocrine neoplasm (MiNEN) consisting of two separate acinar and neuroendocrine components. INSM1 expression overlapped that of synaptophysin and chromogranin A, although in several cases the number of INSM1 positive cells was less than that of chromogranin A. In conclusion, our results show that INSM1 expression in a pancreatic neoplasm should be carefully considered and interpreted in conjunction with morphology and a comprehensive immunohistochemical panel and does not give any diagnostic advantage respect to "traditional" neuroendocrine markers.

It also illustrates the value of a multimodality diagnostic strategy integrating echocardiography, functional oncological imaging, and histopathology in tumour-related cardiac disease. In selected inoperable patients with advanced carcinoid-related tricuspid regurgitation, heterotopic bicaval valve implantation may represent a feasible strategy for reducing venous congestion and improving functional status.

Together, these findings indicate that PIEZO1-related macrophage signaling may participate in TNF-α-associated tumor cell necroptosis in pituitary apoplexy. Pathological necrosis was linked to greater acute symptom burden and perioperative hormonal abnormalities, suggesting that it may identify a clinically severe apoplexy subtype.

These findings indicate that tigecycline exerts potent antiproliferative and antisecretory effects on GH3 cells, likely through Akt/mTOR pathway inhibition, cell cycle arrest, and apoptosis induction. These results provide an experimental foundation for considering tigecycline as a potential therapeutic agent for GH-secreting PitNET.

After stereotactic body radiation therapy (35 Gy in five fractions), persistent uptake was observed 8 months later, suggesting residual viable tumor, which was histopathologically confirmed after resection. 68Ga-DOTATOC PET/CT was useful in evaluating the possibility of recurrence of the soft-tissue lesion, assessing post-radiation viability, and guiding treatment in RCC.